Combining gene expression signatures and autoantibody profiles in human meningioma

Gene Therapy

Volumn 16, Issue 2, 2009, Pages 184-189

  Keller, A ^a   Ludwig, N ^b   Comtesse, N ^b   Henn, W ^b   Steudel, W I ^b   Lenhof, H P ^a   Meese, E ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; KIAA1344 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; MESSENGER RNA; RNA;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; EXPRESSED SEQUENCE TAG; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; MENINGIOMA; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; BLOOD; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PROCEDURES;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MENINGIOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 60449111748     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.130     Document Type: Article

References (18)

1. Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics 2006; 5: 1745-1759.
2. Louis DN, Scheithauer BW, Budka H, Deimling A von, Kepes JJ. Meningeal tumours. In: Kleihues P, Cavenee WK (eds). Pathology and Genetics of Tumours of the Nervous System. IARC Press: Lyon, 2000, pp 175-184.
3. Harada T, Irving RM, Xuereb JH, Barton DE, Hardy DG, Moffat DA et al Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 1996; 84: 847-851.
4. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994; 2: 180-184.
5. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schramm J, Louis DN et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 1995; 4: 827-832.
6. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002; 161: 665-672.
7. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005; 114: 249-256.
8. Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T et al. Genomic expression discovery predicts pathways and opposing functions behind phenotypes. J Biol Chem 2003; 278: 23830-23833.
9. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P et al Molecular signatures define two main classes of meningiomas. Mol Cancer 2007; 6: 64.
10. Keller A, Ludwig N, Comtesse N, Hildebrandt A, Meese E, Lenhof HP. A minimally invasive multiple marker approach allows highly efficient detection of meningioma tumors. BMC Bioinformatics 2006; 7: 539.
11. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U et al. Complex humoral immune response against a benign tumor: Frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci USA 2005; 102: 9601-9606.
12. Comtesse N, Niedermayer I, Glass B, Heckel D, Maldener E, Nastainczyk W et al. MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies. Oncogene 2002; 21: 239-247.
13. Anderson KS, LaBaer J. The sentinel within: Exploiting the immune system for cancer biomarkers. J Proteome Res 2005; 4: 1123-1133.
14. Donnes P, Hoglund A, Sturm M, Comtesse N, Backes C, Meese E et al. Integrative analysis of cancer-related data using CAP. FASEB J 2004; 12: 1465-1467.
15. Fischer U, Struss AK, Hemmer D, Pallasch CP, Steudel WI, Meese E. Glioma-expressed antigen 2 (GLEA2): A novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol 2001; 126: 206-213.
16. Bauer C, Diesinger I, Brass N, Steinhart H, Iro H, Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001; 92: 822-829.
17. Spillmann AA, Bandtlow CE, Lottspeich F, Keller F, Schwab ME. Identification and characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 1998; 273: 19283-19293.
18. Shinohara M, Terada Y, Iwamatsu A, Shinohara A, Mochizuki N, Higuchi M et al. SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature 2002; 416: 759-763.